The Health, Labor and Welfare Ministry approved Wednesday the domestic use of swine flu vaccines made by British and Swiss companies, paving the way for their distribution around early February with inoculations beginning in midmonth.
Japan has concluded import contracts with the two companies, with vaccines for 7.4 million people to be purchased from Britain’s GlaxoSmithKline PLC and 2.5 million from Novartis AG of Switzerland.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.